Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CureVac N.V. (CVAC : NSDQ)

• Company Description    CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany. Number of Employees: 455

• Price / Volume Information    Yesterday's Closing Price: $18.73 Daily Weekly Monthly 20 Day Moving Average: 590,825 shares Shares Outstanding: 187.12 (millions) Market Capitalization: $3,504.78 (millions) Beta: 3.54 52 Week High: $125.66 52 Week Low: $14.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.96% 24.96% 12 Week 11.75% 22.85% Year To Date -45.41% -30.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Friedrich-Miescher-Strasse 15 - Tubingen,2M 72076 DEU ph: 49-70-71988-30 fax: 49-7071-9883 investors@curevac.com http://www.curevac.com

• General Corporate Information    Officers Franz-Werner Haas - Chief Executive Officer Baron Jean Stephenne - Chairman Malte Greune - Chief Operating Officer Pierre Kemula - Chief Financial Officer Ralf Clemens - Director Peer Information CureVac N.V. (CORR.) CureVac N.V. (RSPI) CureVac N.V. (CGXP) CureVac N.V. (BGEN) CureVac N.V. (GTBP) CureVac N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N2451R105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 07/28/22 Share - Related Items Shares Outstanding: 187.12 Most Recent Split Date: (:1) Beta: 3.54 Market Capitalization: $3,504.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.86 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 5.14% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/28/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - 2.63 09/30/21 - 1.79 Quick Ratio 03/31/22 - - 12/31/21 - 2.47 09/30/21 - 1.61 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -400.52 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 4.13 09/30/21 - 4.39 Inventory Turnover 03/31/22 - - 12/31/21 - 2.33 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.04 09/30/21 - 0.04 Debt-to-Capital 03/31/22 - - 12/31/21 - 3.56 09/30/21 - 3.56

Powered by Zacks Investment Research ©